Black Diamond Therapeutics, Inc. Profile Avatar - Palmy Investing

Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic …

Biotechnology
US, Cambridge [HQ]

Government Awards Analysis Beta

Obligations Over-Time

Awards
Obligations

Black Diamond Therapeutics, Inc. has no obligation with a government/award agency.

Latest Obligations

Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0
vs. Previous FY
Contracts
$ 0.0
IDVs
$ 0.0
Direct Payments
$ 0.0
Grants
$ 0.0
Loans
$ 0.0
Other Payments
$ 0.0

Spending By Type

Awards
Obligations

Black Diamond Therapeutics, Inc. can't present spending by time.

Get PRO Today

With PRO you will unlock all insights related to government awards of Black Diamond Therapeutics, Inc..

End of BDTX's Analysis
CIK: 1701541 CUSIP: 09203E105 ISIN: US09203E1055 LEI: - UEI: -
Secondary Listings
BDTX has no secondary listings inside our databases.